Replimune Posts Q1 Results, Names CCO, and Sets 60-Day Launch for TUDRIQEV
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune reported fiscal Q1 2027 results and provided a corporate update. Cash was $195.3 million as of June 30, 2026, down from $268.9 million at fiscal year-end, but the recently completed $150 million financing (net $141.0 million) extends runway to more than twelve months. R&D expenses fell to $49.3 million from $57.8 million a year earlier. The company appointed Michelle DiNapoli as Chief Commercial Officer effective August 18, 2026, bringing 25 years of oncology commercialization experience. TUDRIQEV, approved August 6, is expected to launch within 60 days. This follows the FDA accelerated approval and the $150 million offering announced earlier this month. The commercial launch and confirmatory IGNYTE-3 trial are now funded.
At the time of this announcement, REPL was trading at $14.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $1.50 to $15.71. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.